Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening

Journal of Pediatrics

Volumn 149, Issue 5, 2006, Pages

  Sontag, Marci K ^a   Corey, Mary ^a   Hokanson, John E ^a   Marshall, Julie A ^a   Sommer, Steve S ^a   Zerbe, Gary O ^a   Accurso, Frank J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FECES LIPID; TRYPSINOGEN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DISEASE SEVERITY; FEMALE; GENETIC SCREENING; GENOTYPE; HERITABILITY; HUMAN; IMMUNOREACTIVITY; INFANT; LIPID DIET; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; NEWBORN; NEWBORN SCREENING; PANCREAS DISEASE; PHYSIOLOGY; PRIORITY JOURNAL;

EID: 33751113932     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.07.026     Document Type: Article

References (48)

1. Crossley J.R., Elliott R.B., and Smith P.A. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1 (1979) 472-474
2. Couper R.T., Corey M., Durie P.R., Forstner G.G., and Moore D.J. Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic-sufficient patients with cystic fibrosis. J Pediatr 127 (1995) 408-413
3. Hammond K.B., Abman S.H., Sokol R.J., and Accurso F.J. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med 325 (1991) 769-774
4. Sontag M.K., Hammond K.B., Zielenski J., Wagener J.S., and Accurso F.J. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr 147 (2005) S83-S88
5. Kuczmarski R.J., Ogden C.L., Guo S.S., Grummer-Strawn L.M., Flegal K.M., Mei Z., et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 (2002) 1-190
6. Feranchak A.P., Sontag M.K., Wagener J.S., Hammond K.B., Accurso F.J., and Sokol R.J. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr 135 (1999) 601-610
7. Buzin C.H., Wen C.Y., Nguyen V.Q., Nozari G., Mengos A., Li X., et al. Scanning by DOVAM-S detects all unique sequence changes in blinded analyses: evidence that the scanning conditions are generic. Biotechniques 28 (2000) 746-3
8. Cohn J.A., Neoptolemos J.P., Feng J., Yan J., Jiang Z., Greenhalf W., et al. Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. Hum Mutat 26 (2005) 303-307
9. Bronstein M.N., Sokol R.J., Abman S.H., Chatfield B.A., Hammond K.B., Hambidge K.M., et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 120 (1992) 533-540
10. Van de Kamer J., ten Bokkel Huinink H., and Wegers H. Rapid method for determination of fat in feces. J Biol Chem 177 (1949) 347-355
11. Jeejeebhoy K.N., Ahmad S., and Kozak G. Determination of fecal fats containing both medium and long chain triglycerides and fatty acids. Clin Biochem 3 (1970) 157-163
12. Kristidis P., Bozon D., Corey M., Markiewicz D., Rommens J., Tsui L.C., et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 50 (1992) 1178-1184
13. Tsui L.C. The spectrum of cystic fibrosis mutations. Trends Genet 8 (1992) 392-398
14. Jacqmin-Gadda H., Thiebaut R., Chene G., and Commenges D. Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics 1 (2000) 355-368
15. Thiebaut R., Jacqmin-Gadda H., Leport C., Katlama C., Costagliola D., Le Moing V., et al. Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures. J Biopharm Stat 13 (2003) 271-282
16. Rusakow L.S., Abman S.H., Sokol R.J., Seltzer W.K., Hammond K.B., and Accurso F.J. Immunoreactive trypsinogen levels in infants with cystic fibrosis complicated by meconium ileus. Screening 2 (1993) 13-17
17. Cleghorn G., Benjamin L., Corey M., Forstner G., Dati F., and Durie P. Serum immunoreactive pancreatic lipase and cationic trypsinogen for the assessment of exocrine pancreatic function in older patients with cystic fibrosis. Pediatrics 77 (1986) 301-306
18. Durie P.R., Largman C., Brodrick J.W., Johnson J.H., Gaskin K.J., Forstner G.G., et al. Plasma immunoreactive pancreatic cationic trypsinogen in cystic fibrosis: a sensitive indicator of exocrine pancreatic dysfunction. Pediatr Res 15 (1981) 1351-1355
19. Whitehead F.J., Couper R.T., Moore L., Bourne A.J., and Byard R.W. Dehydration deaths in infants and young children. Am J Forensic Med Pathol 17 (1996) 73-78
20. Waters D.L., Dorney S.F., Gaskin K.J., Gruca M.A., O'Halloran M., and Wilcken B. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program [see comments]. N Engl J Med 322 (1990) 303-308
21. Davis P.B. The gender gap in cystic fibrosis survival. J Gend Specif Med 2 (1999) 47-51
22. Wilschanski M., Zielenski J., Markiewicz D., Tsui L.C., Corey M., Levison H., et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr 127 (1995) 705-710
23. Durie P.R., Gaskin K.J., Geokas M.C., O'Rourke M., and Largman C. Plasma immunoreactive anionic pancreatic trypsin in cystic fibrosis. J Pediatr Gastroenterol Nutr 1 (1982) 337-343
24. Pedemonte N., Lukacs G.L., Du K., Caci E., Zegarra-Moran O., Galietta L.J., et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115 (2005) 2564-2571
25. Suen Y.F., Robins L., Yang B., Verkman A.S., Nantz M.H., and Kurth M.J. Sulfamoyl-4-oxoquinoline-3-carboxamides: novel potentiators of defective DeltaF508-cystic fibrosis transmembrane conductance regulator chloride channel gating. Bioorg Med Chem Lett 16 (2006) 537-540
26. Corey M., Durie P., Moore D., Forstner G., and Levison H. Familial concordance of pancreatic function in cystic fibrosis. J Pediatr 115 (1989) 274-277
27. Kerem B., Rommens J.M., Buchanan J.A., Markiewicz D., Cox T.K., Chakravarti A., et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245 (1989) 1073-1080
28. Borgo G., Mastella G., Gasparini P., Zorzanello A., Doro R., and Pignatti P.F. Pancreatic function and gene deletion F508 in cystic fibrosis. J Med Genet 27 (1990) 665-669
29. Liechti-Gallati S., Bonsall I., Malik N., Schneider V., Kraemer L.G., Ruedeberg A., et al. Genotype/phenotype association in cystic fibrosis: analyses of the delta F508, R553X, and 3905insT mutations. Pediatr Res 32 (1992) 175-178
30. Highsmith Jr. W.E., Burch L.H., Zhou Z., Olsen J.C., Strong T.V., Smith T., et al. Identification of a splice site mutation (2789 +5 G > A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis. Hum Mutat 9 (1997) 332-338
31. Vazquez C., Antinolo G., Casals T., Dapena J., Elorz J., Seculi J.L., et al. Thirteen cystic fibrosis patients, 12 compound heterozygous and one homozygous for the missense mutation G85E: a pancreatic sufficiency/insufficiency mutation with variable clinical presentation. J Med Genet 33 (1996) 820-822
32. Borrego S., Casals T., Dapena J., Fernandez E., Gimenez J., Cabeza J.C., et al. Molecular and clinical analyses of cystic fibrosis in the south of Spain. Clin Genet 46 (1994) 287-290
33. Weller F., Wiebicke W., and Tummler B. [Turkish infant with hypoelectrolytemia and metabolic alkalosis as the sole manifestations of a mild form of cystic fibrosis (mutation D110H)]. Klin Padiatr 212 (2000) 41-43
34. Oates R.D., and Amos J.A. Congenital bilateral absence of the vas deferens and cystic fibrosis. A genetic commonality. World J Urol 11 (1993) 82-88
35. Orozco L., Lezana J.L., Villarreal M.T., Chavez M., and Carnevale A. Mild cystic fibrosis disease in three Mexican delta-F508/G551S compound heterozygous siblings. Clin Genet 47 (1995) 96-98
36. Ferec C., Verlingue C., Guillermit H., Quere I., Raguenes O., Feigelson J., et al. Genotype analysis of adult cystic fibrosis patients. Hum Mol Genet 2 (1993) 1557-1560
37. Cystic Fibrosis Mutation Database [updated 7-13-2005]. Cystic Fibrosis Mutation Consortium. Available online at: http://www.genet.sickkids.on.ca/cftr/.
38. Castaldo G., Fuccio A., Cazeneuve C., Picci L., Salvatore D., Raia V., et al. Detection of five rare cystic fibrosis mutations peculiar to Southern Italy: implications in screening for the disease and phenotype characterization for patients with homozygote mutations. Clin Chem 45 (1999) 957-962
39. Ronchetto P., Telleria Orriols J.J., Fanen P., Cremonesi L., Ferrari M., Magnani C., et al. A nonsense mutation (R1158X) and a splicing mutation (3849 + 4A----G) in exon 19 of the cystic fibrosis transmembrane conductance regulator gene. Genomics 12 (1992) 417-418
40. Schwartz M., Anvret M., Claustres M., Eiken H.G., Eiklid K., Schaedel C., et al. 394delTT: a Nordic cystic fibrosis mutation. Hum Genet 93 (1994) 157-161
41. Wang J., Bowman C.M., and Wong L.J. A novel CFTR frame-shift mutation, 935delA, in two Hispanic cystic fibrosis patients. Mol Genet Metab 70 (2000) 316-321
42. Dork T., Kalin N., Stuhrmann M., Schmidtke J., and Tummler B. A termination mutation (2143delT) in the CFTR gene of German cystic fibrosis patients. Hum Genet 90 (1992) 279-284
43. Zielenski J., Bozon D., Kerem B., Markiewicz D., Durie P., Rommens J.M., et al. Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 10 (1991) 229-235
44. Shoshani T., Augarten A., Yahav J., Gazit E., and Kerem B. Two novel mutations in the CFTR gene: W1089X in exon 17B and 4010delTATT in exon 21. Hum Mol Genet 3 (1994) 657-658
45. Romey M.C., Tuffery S., Desgeorges M., Bienvenu T., Demaille J., and Claustres M. Transcript analysis of CFTR frameshift mutations in lymphocytes using the reverse transcription-polymerase chain reaction technique and the protein truncation test. Hum Genet 98 (1996) 328-332
46. Wong L.J., Wang J., Zhang Y.H., Hsu E., Heim R.A., Bowman C.M., et al. Improved detection of CFTR mutations in Southern California Hispanic CF patients. Hum Mutat 18 (2001) 296-307
47. Alper O.M., Wong L.J., Hostetter G., Cook J., Tenenholz B., Hsu E., et al. 1154insTC is not a rare CFTR mutation. Am J Med Genet A 120 (2003) 294-295
48. Walkowiak J., Herzig K.H., Witt M., Pogorzelski A., Piotrowski R., Barra E., et al. Analysis of exocrine pancreatic function in cystic fibrosis: one mild CFTR mutation does not exclude pancreatic insufficiency. Eur J Clin Invest 31 (2001) 796-801